#Indian #Pharma #Market (IPM) Major Highlights for #September #2015

Indian Pharma market Highlights-Sept-2015

Indian Pharma Market (IPM) Major Highlights for September 2015Sep-15 witnessed a growth of 9.90% for the month. The average Growth of IPM since April has been 13.4%. Anti-Infective and Respiratory Market have pulled the growths down. With Sep – 15 we have closed the 2nd Quarter and the 1st half of fiscal 15-16

September- 15 also witnessed addition of 774 Crs over August-15 which is the lowest since April -15. However the point that also to be noted that Sep 14 was on a high base by adding up 1286 Crs over Sep -13 with a growth of 19.6%

…………………………………………………………………………………….

Companies:

Among the top 10, Zydus* grew by 12.6% followed by Lupin at 12.4% & Sun* at 11.8%
………………………………………………………………………………..
20 corporate have crossed the growth of IPM for the month of September 2015 among top 50
…………………………………………………………………………………………
Among the top 50 Corporate, Wockhardt has the highest growth of 42.3% followed by Troikaa at 38.2% & AstraZeneca at 37.8 %
……………………………………………………………………………….
18 Cos showed growth more than 10% among the top 50
……………………………………………………………………………………..
Among the 11-20 ranked Corporate Intas has the highest growth of 27.4% followed by Micro* at 16.7% & Torrent at 16.0%
……………………………………………………………………………………..
Among the 21-30 ranked Cos, Wockhardt has the highest growth at 42.3% followed by MSD* 33.1% & Novartis at 9.7%
………………………………………………………………………………….
Among the 31-40 ranked Corporate, AstraZeneca has the highest growth at 37.8% followed by Bharat Serums at 19.1% & Wallace* at 19.0%
…………………………………………………………………………………………….
Among the 41-50 ranked Corporate, Troikaa has the highest growth at 38.2% followed by Fourrts at 9.9% & Allergan at 5.5%
…………………………………………………………………………………….
Among the 51-60 ranked Corporate, Boehringer grew at 43.4% followed by Corona at 21.5% & Hegde & Hegde at 19.5%
……………………………………………………………………………….
Among the 61-70 ranked Corporate, Fresenius Kabi grew at 63.7% followed by RPG by 19.4% followed by TTK at 16.3%
……………………………………………………………………………………
Troikka becomes the 50th biggest co on MAT Basis and Wallace 40th biggest co in IPM
……………………………………………………………………………….

DPCO, Non DPCO & Non-Scheduled Para 19 Market:

The DPCO containing molecules market grew at 2.8% whereas the non DPCO market grew by 10.9% & Non -Sch Para 19 Market at 11.5% resulting in an overall growth of 9.9% for September 2015
………………………………………………………………………………..
NLEM & Non – NLEM Category showed unit growth at 1.2% and 1.1% respectively. The Non-Sch Para 19 Market grew at 9.0% from unit perspective
………………………………………………………………………………..
Therapy:
From therapy perspective 12 therapies have outgrown the IPM growth
………………………………………………………………………………..
Gynecological Market grew at 13.4%, Respiratory Market grew at 4.1%, Gastrointestinal market grew at 12.8% , Pain & Analgesics market grew at 9.0% whereas Anti-infectives grew at 3.2%
……………………………………………………………………..
Anti-diabetic market grows at 18.1% & Cardiac at 11.8% in Chronic Business
………………………………………………………………………………..
Derma market grew by 12.9% & Urology Market at 12.1%
…………………………………………………………………………….
Regional Dynamics:
From regional perspective 13 regions have outgrown the IPM growth
………………………………………………………………………………..
UP East market grew the highest at 20.7% followed by Haryana market at 20.6% & Uttarakhand + UP West Market at 18.7%
………………………………………………………………
4 regions had negative growth in September 2015
……………………………………………………..
Molecules:
Amoxycillin + Clavulanic Acid Market grew at 0.6% whereas Glimepiride + Metformin grows at 11.3% at No 2.
…………………………………………………………………………………
The markets of Paracetamol grew at 20.3%, Atorvastatin 2.9%, Probiotic Microbes at 19.7%, Cefixime -3.6%, Pantoprazole 7.5%, Montelukast + Levocetrizine at 5.5%, Glimepiride + Metformin + Pioglitazone at 13.7%, Vitamin-D at 22.3%, Hydroquinone + Mometasone + Tretinoin at 12.3%, Voglibose + Metformin + Glimepiride at 42.9%, Rosuvastatin at 22.0%, Protein Supplements at -2.6%, Azithromycin at -7.0%, Calcium Carbonate + Vit D3 market at 18.1%
…………………………………………………………………………………..
Carica Papaya Market became 6 Crs on MAT Basis
………………………………………………………………………………………
Brands:
Monocef leads the pack with 34 Crs followed by Mixtard, Spasmoproxyvon Plus, Augmentin and Corex for September 15

Spasmoproxyvon Plus grew at 127.3% followed by Janumet at 104%, Corex 44% Among top 10 Brands

Few Brands who have gained ranks include Rotarix (+133), Mifegest Kit (+110), Meronem (+86), Chymoral Forte (+73), Omez (+50), Trajenta (+44), Betnovate C (+41), Vertin (+40), Janumet (+39), Rantac (+32), Panderm Plus, Istamet (+31), Betnesol (+29), levipil (+28), Spasmoproxyvon Plus (+25), Rosuvas (+24), Shelcal (+16), Dolo (+12), Orofer XT (+11), Among top 100 Brands over September -14
………………………………………………………………………………………..
Caripill moves into Top 500 Brands for the month of Sep -15
…………………………………………………………………………..
300th Biggest Brand is Gestofit from Alembic
………………………………………………………………………………….
New Launches in IPM:

Total 253 Brands & 437 SKUs launched in September 2015

Top New Brands for September -15 are Vilazine, Lupiheme & Vilano

Biggest New Launch by an MNC are Amicolon SB, Stugeron Plus & BHRF in September 2015

Source: AIOCD Pharmasofttech AWACS

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s